Celyad Oncology Sa Stock Net Income
| CLYYF Stock | USD 0.15 0.00 0.00% |
As of the 5th of February, Celyad Oncology shows the Standard Deviation of 2.38, risk adjusted performance of (0.12), and Mean Deviation of 0.7836. Celyad Oncology SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Celyad Oncology SA standard deviation and skewness to decide if Celyad Oncology SA is priced correctly, providing market reflects its regular price of 0.15 per share. As Celyad Oncology SA appears to be a penny stock we also recommend to validate its information ratio numbers.
Celyad Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Celyad Oncology's valuation are provided below:Celyad Oncology SA does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Celyad |
Celyad Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Celyad Oncology's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Celyad Oncology.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Celyad Oncology on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Celyad Oncology SA or generate 0.0% return on investment in Celyad Oncology over 90 days. Celyad Oncology is related to or competes with Molecular Partners, XORTX Therapeutics, Nutriband, ZyVersa Therapeutics, Allarity Therapeutics, Aditxt, and Palisade Bio. Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric ant... More
Celyad Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Celyad Oncology's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Celyad Oncology SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 16.67 |
Celyad Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celyad Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Celyad Oncology's standard deviation. In reality, there are many statistical measures that can use Celyad Oncology historical prices to predict the future Celyad Oncology's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (1.35) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Celyad Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Celyad Oncology February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (1.34) | |||
| Mean Deviation | 0.7836 | |||
| Coefficient Of Variation | (588.10) | |||
| Standard Deviation | 2.38 | |||
| Variance | 5.65 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | (1.35) | |||
| Maximum Drawdown | 16.67 | |||
| Skewness | (6.13) | |||
| Kurtosis | 38.36 |
Celyad Oncology SA Backtested Returns
Celyad Oncology SA secures Sharpe Ratio (or Efficiency) of -0.17, which signifies that the company had a -0.17 % return per unit of risk over the last 3 months. Celyad Oncology SA exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Celyad Oncology's Risk Adjusted Performance of (0.12), standard deviation of 2.38, and Mean Deviation of 0.7836 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Celyad Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Celyad Oncology is expected to be smaller as well. At this point, Celyad Oncology SA has a negative expected return of -0.42%. Please make sure to confirm Celyad Oncology's standard deviation and skewness , to decide if Celyad Oncology SA performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.52 |
Modest predictability
Celyad Oncology SA has modest predictability. Overlapping area represents the amount of predictability between Celyad Oncology time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Celyad Oncology SA price movement. The serial correlation of 0.52 indicates that about 52.0% of current Celyad Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.52 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Celyad Oncology SA reported net income of (26.51 Million). This is 107.77% lower than that of the Healthcare sector and 137.85% lower than that of the Biotechnology industry. The net income for all United States stocks is 104.64% higher than that of the company.
Celyad Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celyad Oncology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Celyad Oncology could also be used in its relative valuation, which is a method of valuing Celyad Oncology by comparing valuation metrics of similar companies.Celyad Oncology is currently under evaluation in net income category among its peers.
Celyad Fundamentals
| Return On Equity | -0.93 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | 11.81 M | |||
| Shares Outstanding | 22.59 M | |||
| Shares Owned By Insiders | 8.83 % | |||
| Shares Owned By Institutions | 24.19 % | |||
| Price To Book | 5.05 X | |||
| Price To Sales | 24,222 X | |||
| Gross Profit | 5 K | |||
| EBITDA | (24.73 M) | |||
| Net Income | (26.51 M) | |||
| Cash And Equivalents | 6.1 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.87 M | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 0.97 X | |||
| Book Value Per Share | 1.36 X | |||
| Cash Flow From Operations | (26.64 M) | |||
| Earnings Per Share | (1.51) X | |||
| Number Of Employees | 95 | |||
| Beta | 1.76 | |||
| Market Capitalization | 5.65 M | |||
| Total Asset | 79.94 M | |||
| Z Score | 0.6 | |||
| Net Asset | 79.94 M |
About Celyad Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Celyad Oncology SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celyad Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celyad Oncology SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Celyad Pink Sheet
Celyad Oncology financial ratios help investors to determine whether Celyad Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celyad with respect to the benefits of owning Celyad Oncology security.